Foundation Medicine Company Profile (NASDAQ:FMI)

About Foundation Medicine (FMI)

Foundation Medicine logoFoundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company's segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FMI
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $32.90
  • 50 Day Moving Average: $27.61
  • 200 Day Moving Average: $22.82
  • 52-Week Range: $35,418,000.00 - $15.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.22
  • P/E Growth: 0.00
  • Market Cap: $1.17B
  • Outstanding Shares: 35,418,000
  • Beta: -0.2
  • Net Margins: -84.67%
  • Return on Equity: -42.21%
  • Return on Assets: -35.70%
  • Current Ratio: 5.04%
  • Quick Ratio: 4.74%

Analyst Ratings

Consensus Ratings for Foundation Medicine (NASDAQ:FMI) (?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $28.00 (14.89% downside)

Analysts' Ratings History for Foundation Medicine (NASDAQ:FMI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/7/2017Janney Montgomery ScottUpgradeSell -> Neutral$31.00N/AView Rating Details
11/3/2016Benchmark Co.DowngradeBuy -> HoldN/AView Rating Details
8/4/2016BTIG ResearchReiterated RatingHoldN/AView Rating Details
8/3/2016JPMorgan Chase & Co.Reiterated RatingHold$25.00N/AView Rating Details
5/4/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
2/26/2016Goldman Sachs Group IncLower Price TargetNeutral$17.00 -> $15.00N/AView Rating Details
11/4/2015WedbushLower Price TargetNeutral$26.00 -> $19.00N/AView Rating Details
9/16/2015Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
7/30/2015JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 3/26/2015 forward)


Earnings History for Foundation Medicine (NASDAQ:FMI)
Earnings by Quarter for Foundation Medicine (NASDAQ:FMI)
Earnings History by Quarter for Foundation Medicine (NASDAQ:FMI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2017Q416($0.96)($1.02)$29.23 million$28.80 millionViewListenView Earnings Details
11/2/2016Q316($0.88)($0.90)$28.70 million$29.43 millionViewN/AView Earnings Details
8/2/2016Q216($0.79)($0.84)$26.72 million$28.24 millionViewN/AView Earnings Details
5/3/2016Q116($0.72)($0.50)$25.20 million$30.40 millionViewN/AView Earnings Details
2/23/2016Q415($0.67)($0.55)$25.76 million$26.10 millionViewListenView Earnings Details
11/3/2015Q315($0.56)($0.60)$24.04 million$25.40 millionViewListenView Earnings Details
7/29/2015Q215($0.56)($0.98)$24.44 million$22.50 millionViewListenView Earnings Details
5/11/2015Q115($0.53)($0.59)$21.00 million$19.30 millionViewListenView Earnings Details
2/24/2015Q314($0.51)($0.47)$18.05 million$18.70 millionViewListenView Earnings Details
11/5/2014Q3($0.48)($0.46)$15.60 million$16.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.48)($0.49)$13.39 million$14.50 millionViewN/AView Earnings Details
5/7/2014Q114($0.48)($0.44)$11.33 million$11.45 millionViewN/AView Earnings Details
2/25/2014Q413($0.43)($0.48)$9.01 million$9.66 millionViewN/AView Earnings Details
11/6/2013($0.51)($3.51)$6.92 million$8.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Foundation Medicine (NASDAQ:FMI)
Current Year EPS Consensus Estimate: $-3.95 EPS
Next Year EPS Consensus Estimate: $-3.22 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.60)($0.58)($0.59)
Q2 20162($0.58)($0.58)($0.58)
Q3 20162($0.55)($0.54)($0.55)
Q4 20162($0.53)($0.48)($0.51)
(Data provided by Zacks Investment Research)


Dividend History for Foundation Medicine (NASDAQ:FMI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Foundation Medicine (NASDAQ:FMI)
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 31.44%
Insider Trades by Quarter for Foundation Medicine (NASDAQ:FMI)
Institutional Ownership by Quarter for Foundation Medicine (NASDAQ:FMI)
Insider Trades by Quarter for Foundation Medicine (NASDAQ:FMI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2017Jason RyanCFOSell12,500$31.68$396,000.00View SEC Filing  
3/16/2017Robert W HessleinSVPSell6,231$31.67$197,335.77View SEC Filing  
3/8/2017Michael J PelliniDirectorSell40,000$34.30$1,372,000.00View SEC Filing  
2/8/2017Steven J KafkaCOOSell10,415$23.24$242,044.60View SEC Filing  
1/13/2017Jason RyanCFOSell1,777$19.00$33,763.00View SEC Filing  
1/4/2017David DalyInsiderSell5,097$17.91$91,287.27View SEC Filing  
1/4/2017Jason RyanCFOSell4,665$17.74$82,757.10View SEC Filing  
1/4/2017Michael J. PelliniCEOSell14,637$17.67$258,635.79View SEC Filing  
1/4/2017Robert W. HessleinSVPSell4,682$17.74$83,058.68View SEC Filing  
1/4/2017Steven J. KafkaCOOSell8,390$17.72$148,670.80View SEC Filing  
12/1/2016David DalyInsiderSell564$19.95$11,251.80View SEC Filing  
11/22/2016Steven J KafkaCOOSell6,273$23.01$144,341.73View SEC Filing  
10/20/2016Jason RyanCFOSell506$22.45$11,359.70View SEC Filing  
10/20/2016Steven J KafkaCOOSell4,427$23.00$101,821.00View SEC Filing  
10/4/2016David DalyInsiderSell2,045$23.65$48,364.25View SEC Filing  
10/4/2016Michael J. PelliniCEOSell2,629$23.65$62,175.85View SEC Filing  
10/4/2016Robert W. HessleinSVPSell1,220$23.65$28,853.00View SEC Filing  
10/4/2016Steven J. KafkaCOOSell2,135$23.62$50,428.70View SEC Filing  
9/20/2016Steven J KafkaCOOSell9,469$23.70$224,415.30View SEC Filing  
8/19/2016Jason RyanCFOSell13,863$23.92$331,602.96View SEC Filing  
7/5/2016David DalyInsiderSell5,008$17.76$88,942.08View SEC Filing  
7/5/2016Jason RyanCFOSell4,687$17.63$82,631.81View SEC Filing  
7/5/2016Michael J. PelliniCEOSell10,160$17.63$179,120.80View SEC Filing  
7/5/2016Robert W. HessleinSVPSell4,705$17.62$82,902.10View SEC Filing  
7/5/2016Steven J. KafkaCOOSell6,495$17.67$114,766.65View SEC Filing  
6/3/2016David DalyInsiderSell472$21.66$10,223.52View SEC Filing  
4/1/2016Steven J KafkaCOOSell124$18.08$2,241.92View SEC Filing  
4/1/2016Vincent A MillerInsiderSell356$18.08$6,436.48View SEC Filing  
12/1/2015David DalyInsiderSell2,559$16.78$42,940.02View SEC Filing  
11/13/2015Michael J PelliniCEOBuy9,100$16.43$149,513.00View SEC Filing  
6/15/2015Krishna YeshwantDirectorSell183,860$32.98$6,063,702.80View SEC Filing  
4/7/2015Alexis BorisyDirectorSell234,542$50.00$11,727,100.00View SEC Filing  
4/7/2015Roche Holdings IncInsiderBuy15,604,288$50.00$780,214,400.00View SEC Filing  
4/7/2015Rock Ventures Lp ThirdMajor ShareholderSell3,976,278$50.00$198,813,900.00View SEC Filing  
3/5/2015Michael J PelliniCEOSell153,300$47.24$7,241,892.00View SEC Filing  
1/15/2015Steven J KafkaCOOSell15,000$48.38$725,700.00View SEC Filing  
1/12/2015Michael J PelliniCEOSell22,500$51.07$1,149,075.00View SEC Filing  
1/12/2015Robert W HessleinSVPSell7,000$52.11$364,770.00View SEC Filing  
1/12/2015Steven J KafkaCOOSell8,000$51.83$414,640.00View SEC Filing  
1/12/2015Vincent A MillerInsiderSell2,000$53.03$106,060.00View SEC Filing  
1/8/2015Robert W HessleinSVPSell4,000$23.03$92,120.00View SEC Filing  
12/29/2014Michael J PelliniCEOSell12,500$23.91$298,875.00View SEC Filing  
11/17/2014Jason RyanSVPSell3,541$24.90$88,170.90View SEC Filing  
11/14/2014Michael J PelliniCEOSell12,500$24.91$311,375.00View SEC Filing  
10/27/2014Jason RyanSVPSell2,360$25.00$59,000.00View SEC Filing  
10/27/2014Steven J KafkaCOOSell10,000$25.31$253,100.00View SEC Filing  
9/15/2014Jason RyanSVPSell2,361$21.92$51,753.12View SEC Filing  
8/18/2014Michael J PelliniCEOSell12,500$25.29$316,125.00View SEC Filing  
7/22/2014Steven J KafkaCOOSell10,000$27.14$271,400.00View SEC Filing  
7/15/2014Jason RyanSVPSell3,541$27.22$96,386.02View SEC Filing  
7/15/2014Vincent A MillerInsiderSell15,000$27.25$408,750.00View SEC Filing  
7/8/2014Robert W HessleinSVPSell4,000$27.22$108,880.00View SEC Filing  
7/2/2014Michael J PelliniCEOSell15,000$27.42$411,300.00View SEC Filing  
6/26/2014Jason RyanSVPSell1,180$25.00$29,500.00View SEC Filing  
6/26/2014Steven J KafkaCOOSell5,000$25.19$125,950.00View SEC Filing  
6/19/2014Steven J KafkaCOOSell5,000$24.46$122,300.00View SEC Filing  
6/16/2014Jason RyanSVPSell2,361$22.61$53,382.21View SEC Filing  
6/13/2014Krishna YeshwantDirectorSell1,300,000$22.40$29,120,000.00View SEC Filing  
6/5/2014Jason RyanSVPSell10,000$24.06$240,600.00View SEC Filing  
6/5/2014Steven J KafkaCOOSell4,500$24.19$108,855.00View SEC Filing  
5/6/2014Vincent MillerInsiderSell3,000$30.00$90,000.00View SEC Filing  
4/16/2014Jason RyanSVPSell3,541$26.36$93,340.76View SEC Filing  
4/16/2014Vincent MillerInsiderSell30,000$26.86$805,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Foundation Medicine (NASDAQ:FMI)
Latest Headlines for Foundation Medicine (NASDAQ:FMI)
DateHeadline logoFoundation Medicine Inc (FMI) Rating Increased to Hold at Zacks Investment Research - March 24 at 11:46 AM logoFoundation Medicine Inc (FMI) CFO Sells $396,000.00 in Stock - March 20 at 7:52 PM logoFoundation Medicine Inc (FMI) SVP Sells $197,335.77 in Stock - March 20 at 4:31 PM logoFoundation Medicine Inc (FMI) Given Consensus Recommendation of “Hold” by Analysts - March 10 at 12:38 PM logoFoundation Medicine Inc (FMI) Upgraded to Hold at Zacks Investment Research - March 9 at 11:33 PM logoFoundation Medicine Inc (FMI) Director Sells $1,372,000.00 in Stock - March 9 at 6:30 PM logoFoundation Medicine Inc. (FMI) Surged To A New High For The Year - March 7 at 11:35 AM logoFoundation Medicine (FMI) Jumps: Stock Adds 10.6% in Session - March 7 at 11:35 AM logo5:02 pm Foundation Medicine receives Medicare payment in non-small cell lung cancer under a Local Coverage Determination for FoundationOne, the company's comprehensive genomic profiling assay - March 2 at 10:31 PM logoFoundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage ... - Business Wire (press release) - March 2 at 5:30 PM logoFoundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company’s Comprehensive Genomic Profiling Assay - March 2 at 5:30 PM logoFOUNDATION MEDICINE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - March 2 at 5:30 PM logoFoundation Medicine to Present at Cowen and Company’s 37th Annual Healthcare Conference - February 28 at 8:33 AM logoEdited Transcript of FMI earnings conference call or presentation 22-Feb-17 9:30pm GMT - February 23 at 5:15 PM logoBRIEF-Foundation Medicine Q4 loss per share $1.02 - February 22 at 10:32 PM logoFoundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook - February 22 at 10:32 PM logoIs the Options Market Predicting a Spike in Foundation Medicine (FMI) Stock? - Nasdaq - February 16 at 5:12 PM logoIs the Options Market Predicting a Spike in Foundation Medicine (FMI) Stock? - February 16 at 5:12 PM logoFoundation Medicine (FMI) Spikes Following Tuesday - February 8 at 5:45 PM logoFoundation Medicine Announces Timing for Fourth Quarter and Year-End 2016 Financial Results and Conference Call - February 6 at 11:21 AM logoBRIEF-Discovery Group I LLC reports 5.2 pct stake in Foundation Medicine as of Jan 19 - SEC Filing - January 30 at 5:59 PM logo[$$] Third Rock Ventures Adds Partner Focused on HR - January 28 at 12:00 AM logoImplied Volatility Surging for Foundation Medicine (FMI) Stock Options - Nasdaq - January 23 at 5:35 PM logoImplied Volatility Surging for Foundation Medicine (FMI) Stock Options - January 23 at 10:54 AM logoBaron Funds Comments on Foundation Medicine - January 20 at 6:34 PM logoFoundation Medicine (FMI): Moving Average Crossover Alert - Nasdaq - January 13 at 3:43 AM logoFoundation Medicine (FMI): Moving Average Crossover Alert - January 12 at 5:40 PM logoFoundation Medicine Reports Preliminary 2016 Results - January 9 at 6:04 PM logoFOUNDATION MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial - January 9 at 6:04 PM logoBRIEF-Foundation Medicine Inc says Pellini named chairman of company's board - January 6 at 5:46 PM logoFoundation Medicine (FMI) Says Troy Cox to Succeed Michael Pellini as CEO - January 6 at 5:46 PM logoCambridge's Foundation Medicine gets new CEO in leadership shuffle - January 6 at 5:46 PM logoFOUNDATION MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh - January 6 at 5:46 PM logoFoundation Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference - January 3 at 12:11 PM


Frequently Asked Questions for Foundation Medicine (NASDAQ:FMI)

What is Foundation Medicine's stock symbol?

Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."

How were Foundation Medicine's earnings last quarter?

Foundation Medicine Inc (NASDAQ:FMI) released its quarterly earnings data on Wednesday, February, 22nd. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by $0.06. The company had revenue of $28.80 million for the quarter, compared to analysts' expectations of $29.23 million. Foundation Medicine had a negative net margin of 84.67% and a negative return on equity of 42.21%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company posted ($0.55) EPS.

When will Foundation Medicine make its next earnings announcement?

Foundation Medicine is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

Where is Foundation Medicine's stock going? Where will Foundation Medicine's stock price be in 2017?

5 analysts have issued 1 year target prices for Foundation Medicine's shares. Their forecasts range from $25.00 to $31.00. On average, they anticipate Foundation Medicine's stock price to reach $28.00 in the next twelve months.

Who owns Foundation Medicine stock?

Foundation Medicine's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Discovery Group I LLC (4.55%), ARK Investment Management LLC (0.85%), State Street Corp (0.63%), Baillie Gifford & Co. (0.50%), FMR LLC (0.26%) and Russell Investments Group Ltd. (0.09%). Company insiders that own Foundation Medicine stock include Alexis Borisy, David Daly, Jason Ryan, Krishna Yeshwant, Michael J Pellini, Robert W Hesslein, Roche Holdings Inc, Rock Ventures Lp Third, Steven J Kafka and Vincent A Miller.

Who sold Foundation Medicine stock? Who is selling Foundation Medicine stock?

Foundation Medicine's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. Company insiders that have sold Foundation Medicine stock in the last year include David Daly, Jason Ryan, Michael J Pellini, Robert W Hesslein, Steven J Kafka and Vincent A Miller.

Who bought Foundation Medicine stock? Who is buying Foundation Medicine stock?

Foundation Medicine's stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Discovery Group I LLC, Russell Investments Group Ltd., Moloney Securities Asset Management LLC, State Street Corp, GSA Capital Partners LLP, Metropolitan Life Insurance Co. NY and Commerzbank Aktiengesellschaft FI. Company insiders that have bought Foundation Medicine stock in the last two years include Michael J Pellini and Roche Holdings Inc.

How do I buy Foundation Medicine stock?

Shares of Foundation Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Foundation Medicine stock cost?

One share of Foundation Medicine stock can currently be purchased for approximately $32.90.

Foundation Medicine (FMI) Chart for Sunday, March, 26, 2017

This page was last updated on 3/26/2017 by Staff